



Protein degraded.  
Disease targeted.  
Lives transformed.

October 2024



# Forward-looking Statements and Intellectual Property

## Forward-looking Statements

The following presentation contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. These forward-looking statements include, but are not limited to, statements regarding the therapeutic potential of C4 Therapeutics, Inc.’s technology and products. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, as well as the fact that the product candidates that we are developing or may develop may not demonstrate success in clinical trials. Prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The forward-looking statements included in this presentation are subject to a variety of risks and uncertainties, including those set forth in our most recent and future filings with the Securities and Exchange Commission. Our actual results could vary significantly from those anticipated in this presentation, and our financial condition and results of operations could be materially adversely affected. C4 Therapeutics, Inc. undertakes no obligation to update or revise the information contained in this presentation, whether as a result of new information, future events or circumstances or otherwise.


## Intellectual Property

C4 Therapeutics, Inc. owns various registered and unregistered trademarks, service marks, and trade names in the U.S. and internationally, including, without limitation, C4 THERAPEUTICS, our housemark logo, the name of our TORPEDO platform, and the names of our BIDAC and MONODAC degrader products. All trademarks, service marks, or trade names referred to in this presentation that we do not own are the property of their respective owners. Solely for convenience, the trademarks, service marks, and trade names in this presentation are referred to without the symbols <sup>®</sup>, <sup>SM</sup> and <sup>TM</sup>, but those references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights to.

# C4T Is a Recognized Leader in Delivering on the Promise of Targeted Protein Degradation

## Our Mission

To deliver on the promise of targeted protein degradation science to create a new generation of medicines that transform patients' lives



## WORLD-CLASS DEGRADER PLATFORM

Robust patent portfolio of novel cereblon binders; Demonstrated ability to design **orally bioavailable, catalytically efficient degraders**

## RIGOROUS TARGET SELECTION

Focus on targets with a **clear degrader rationale**

## BROAD DEGRADER APPROACH


**MonoDAC** and **BiDAC** degraders, as well as **degrader-antibody conjugates**

## CLINICAL PIPELINE

**Oncology degraders** against targets of high unmet need

# Designed and Advanced Degraders Into the Clinic Across a Range of Target Classes, Demonstrating Robust Target Degradation


## Interrogated Diverse Target Classes




## Attained IND Clearance



## Achieved Desirable Drug-like Properties



## Degraded Target as Predicted



- ✓ Discovered degraders and advanced **4 INDs** against a transcription factor, a chromatin modifier, and two kinases
- ✓ Have evaluated **3 programs** in the clinic, each demonstrating robust target degradation in patients
- ✓ Delivered **two development candidates** to our collaboration partner, Biogen

Investigational New Drug Applications (INDs)

# Advancing a Broad Pipeline to Deliver Near-Term Value

Program	Target	Indications	Discovery	Preclinical	Early Phase Development	Late Phase Development	Rights
<b>Cemsidomide</b>	<b>IKZF1/3</b>	Multiple Myeloma & Non-Hodgkin's Lymphoma					
<b>CFT1946</b>	<b>BRAF V600 Mutant</b>	V600 Mutant Cancers					
<b>CFT8919<sup>1</sup></b>	<b>EGFR L858R</b>	Non-Small Cell Lung Cancer					
<b>Discovery Stage Programs</b>	Various Cancers						
<b>Collaboration Programs</b>	Autoimmune & Cancer	2 targets					
	Cancer	2 targets					Merck KGaA Darmstadt, Germany
	Cancer	1 target					
	Autoimmune & Neurological	2 targets					

<sup>1</sup>License and collaboration agreement with Betta Pharmaceuticals for development and commercialization in Greater China; <sup>2</sup>Delivered development candidates to Biogen in Q1 2024 and Q3 2024

# C4T is On Track to Achieve All 2024 Goals, Progressing Multiple Clinical and Preclinical Programs

## Cemsidomide IKZF1/3

- **ASH 2024 (Dec.):** Present updated data from Phase 1 dose escalation +dex trial in R/R MM
- **ASH 2024 (Dec.):** Present data from Phase 1 dose escalation monotherapy trial in R/R NHL
- **By YE 2024:** Complete Phase 1 dose exploration in R/R MM and R/R NHL

## CFT1946 BRAF V600 Mutant

- ✓ **2Q 2024:** Present preclinical data demonstrating differentiated activity in BRAF V600 mutant driven melanoma, CRC, NSCLC, and brain metastasis models at AACR
- ✓ **ESMO Congress 2024:** Present monotherapy data from Phase 1 dose escalation trial in melanoma, CRC, NSCLC and other BRAF V600 mutant driven cancers

## CFT8919 EGFR L858R

- ✓ **2024:** Support trial start-up activities related to Betta's Phase 1 dose escalation trial in China

## Discovery

- ✓ **1Q 2024:** Collaboration with Merck KGaA, Darmstadt, Germany to discover two targeted protein degraders against critical oncogenic proteins
- ✓ **2024:** Deliver development candidate to collaboration partner

**Runway into 2027, Beyond Value Inflection Milestones**

Relapsed or refractory multiple myeloma (R/R MM); Relapsed or refractory non-Hodgkin lymphoma (R/R NHL); Colorectal cancer (CRC); Non-small cell lung cancer (NSCLC)

# Cemsidomide


*Targeting IKZF1 /3*

Multiple Myeloma (MM)  
& Non-Hodgkin's Lymphoma (NHL)


# IKZF1/3 Degradation Drives Three Distinct Areas of Hematopoietic Biology; Degradating IKZF1/3 Is a Validated Therapeutic Strategy in MM and NHL

## IKZF1 / IKZF3 Transcription Factors


### Drive MM and NHL Cell Growth and Survival



### Activate Fully Differentiated T-cells



### Regulate Hematopoietic Stem Cell Differentiation



## Consequences of IKZF1/3 Degradation:

- MM and NHL Cell Death

- T-cell Activation

- On-target Neutropenia

Ikaros Family Zinc Finger proteins 1 and 3 (IKZF1/3); Multiple Myeloma (MM); Non-Hodgkin's Lymphoma (NHL)



# Cemsidomide Has the Potential to Address Multiple Opportunities Across MM and NHL



**Annual  
U.S.  
Incidence**



**Market Size<sup>3</sup>**




**Unmet Needs**

		2023	2030 <sup>4</sup>	
<b>Multiple Myeloma</b>		~36,000 <sup>1</sup>	~\$21B → ~\$42B	<ul style="list-style-type: none"> <li>• Additional efficacious and tolerable agents that work well in combination regimens</li> <li>• Therapies that increase the durability of t-cell engagers (i.e., prevention of T-cell exhaustion)</li> </ul>
<b>Non-Hodgkin's Lymphoma</b>	<i>All Subtypes</i>	~80,000 <sup>1</sup>	~\$14B → ~\$30B	<ul style="list-style-type: none"> <li>• Treatment options for post-CAR-T patients</li> <li>• Therapies for those not fit for intensive chemo</li> <li>• Effective frontline and 2L+ therapies for certain subtypes (e.g., PTCL)</li> </ul>
	<i>Peripheral T-Cell Lymphoma</i>	~5,000 <sup>2</sup>	~\$660M → ~\$1.1B	<ul style="list-style-type: none"> <li>• Effective targeted therapies, biologics (aside from CD30+ patients), and CAR-Ts</li> <li>• Treatment options for R/R patients</li> </ul>

Sources: 1. NCI SEER, 2. Lymphoma Research Foundation, 3. EvaluatePharma, 4. Consensus analyst forecasts.

# Cemsidomide Phase 1 Dose Escalation Trial's Goal Is to Define the Safety Profile and Identify Signs of Anti-Tumor Activity in R/R MM and R/R NHL

## Phase 1 Dose Escalation Trial



## Endpoints

### Primary:

- Safety and tolerability
- Determine the maximum tolerated doses

### Secondary:

- Estimate anti-tumor activity
- Assess PK

### Exploratory:

- Characterize target engagement
- Assess kinetics, depth, recovery and consistency of target engagement
- Assess immunomodulation

Pharmacokinetic (PK); Monday, Wednesday, Friday dosing (MWF); once daily (QD); Relapsed refractory multiple myeloma (R/R MM); Relapsed refractory non-Hodgkin's lymphoma (R/R NHL); Dexamethasone (Dex)

# Prior Data Demonstrated Cemsidomide as a Potential MM Therapy



Established Safety Profile  
and Dosing Schedule




Demonstrated  
Monotherapy Activity



Promising Responses with  
Cemsidomide +  
Dexamethasone

Cemsidomide is a **potential treatment for multi-refractory MM patients** with the ability **to move into earlier lines** with numerous combination opportunities

# Clinical Evidence of Immune T-cell Activation With Cemsidomide Monotherapy



- 19 patient samples (PBMCs) analyzed by flow cytometry
- Aggregate data of 25  $\mu$ g, 50  $\mu$ g, and 75  $\mu$ g MWF and QD

**Supports potential of cemsidomide as a maintenance therapy option and in combination with novel MM agents to improve efficacy:**


- ✓ Cemsidomide induces CD8+ T-cell activation by increasing effector memory T-cell subset
- ✓ T-cell activation is observed at well-tolerated monotherapy clinical doses
- ✓ Clinical data consistent with the preclinical *in vitro* data reported for cemsidomide

Peripheral Blood Mononuclear Cells (PBMCs); Daily dosing (QD); Monday, Wednesday, Friday Dosing Schedule (MWF); Multiple Myeloma (MM)  
Source: C4T data on file as of 11/28/2023

# Cemsidomide Combined With Novel MM Agents Demonstrated Enhanced Immune Cell Lysis in Non-clinical Translational Models


## Daratumumab (Anti-CD38) Combo

Antibody-Dependent Cell-Mediated Cytotoxicity Assay (ADCC)



## Teclistamab (BCMA BiTE) Combo

T-cell Dependent Cellular Cytotoxicity Assay (TDCC)




$C_{min}$  and  $C_{max}$  represent human plasma concentrations for a 50  $\mu$ g dose of cemsidomide

# Cemsidomide + Dexamethasone Dose Escalation in R/R MM Continues to Progress

## KEY INCLUSION CRITERIA

- Adults with R/R MM, at least 3 prior lines that have included lenalidomide, pomalidomide, a proteasome inhibitor, a glucocorticoid, and an anti-CD38 monoclonal antibody
- Nonresponsive to or progressed within 60 days of prior therapy
- Measurable disease
- Adequate bone marrow function (ANC  $\geq 1000$ , Hgb  $\geq 8.0$ , platelets  $\geq 75,000$ )
- Creatinine clearance  $\geq 40$  mL/min
- ECOG  $\leq 2$

## Phase 1: Dose Escalation + Dexamethasone 14 Days On/14 Days Off



- Patients enrolling at the 100 µg dose level
- Dose escalation continues as maximum tolerated dose has not yet been reached

## Phase 2



Cohort Expansion  
N=~30

Eastern Cooperative Oncology Group (ECOG); Monday, Wednesday, Friday dosing (MWF); Daily Dosing (QD); Relapsed/Refractory multiple myeloma (R/R MM); Absolute neutrophil count (ANC); Hemoglobin (Hgb); Dexamethasone (Dex); Dose level (DL)

\*+Dex is dosed on days 1, 8, 15, and 22 and dose is reduced for older patients.

# Cemsidomide + Dexamethasone Is Well Tolerated and Shows Best Responses in Patients Refractory to BCMA Therapies, Updated Data to be Presented at ASH

## Anti-myeloma Activity:




## Safety:

- Cemsidomide + dexamethasone is well tolerated
- Consistent with the monotherapy safety signal
- No AEs have led to dose reductions, discontinuations or DLTs

Extramedullary Disease (EMD); T-Cell Engager (TCE); Daily Dosing (QD); One Weekly (QW); Monday, Wednesday, Friday Dosing (MWF); Dose Limiting Toxicity (DLTs); Dexamethasone (dex); B cell maturation antigen (BCMA); Adverse events (AEs)  
 Source: C4T data on file as of 11/28/2023

# Cemsidomide Profile Supports Multiple Opportunities Across MM Landscape



\* Other combination opportunities may include CAR-T, anti-SLAMF7, XPO1 inhibitors, FcRH5 BiTE, among others.

Bi-specific T-cell Engager (BiTE); Proteasome Inhibitors (PI); Multiple myeloma (MM); B cell maturation antigen (BCMA); G protein-coupled receptor, class C, group 5, member D (GPRC5D)




# Cemsidomide Monotherapy Dose Escalation in R/R NHL Continues to Progress, Initial Data to be Presented at ASH

## KEY INCLUSION CRITERIA

- Adults with R/R NHL, with minimum prior lines of therapy required for each NHL sub-type:
  - PTCL: At least 1, including alkylator chemotherapy
  - MCL: At least 2, including CD20 antibody and alkylator chemotherapy
  - FL: At least 2, including CD20 antibody and alkylator chemotherapy
  - DLBCL: At least 2, including CD20 antibody therapy and prior autologous bone marrow transplant (or ineligible for transplant)
  - Other: Treated or refused treatment with any SOC therapies known to provide clinical benefit
- Measurable disease
- Adequate organ function
- ECOG  $\leq 2$

## Phase 1: Dose Escalation Monotherapy 14 Days On/14 Days Off



- 100 µg is the highest dose evaluated to date
- Dose escalation continues as maximum tolerated dose has not yet been reached

Eastern Cooperative Oncology Group (ECOG); Monday, Wednesday, Friday dosing (MWF); Daily Dosing (QD); Relapsed/Refractory non-Hodgkin's lymphoma (R/R NHL); Peripheral T-cell lymphoma (PTCL); Mantle cell lymphoma (MCL); Follicular lymphoma (FL); Diffuse large B-cell lymphoma (DLBCL); Dose level (DL); Eastern Cooperative Oncology Group (ECOG); SOC (standard of care)

# CFT1946

*Targeting BRAF V600 Mutant*

Melanoma, Colorectal (CRC)  
& Non-Small Cell Lung Cancer (NSCLC)

# CFT1946 Has the Potential to Overcome Several Shortcomings Seen With Inhibitors for BRAF V600X Cancers

## Key Limitations of Approved BRAF Inhibitors:

- **Durable and deep responses are often not seen** in melanoma, NSCLC and CRC patients, due to **MAPK pathway resistance**
- **Poor tolerability**, such as high-rates of cutaneous adverse events
- Often **combined with a MEK inhibitor to enhance both efficacy and minimize side effects resulting from paradoxical activation** by BRAF inhibitors
- **Limited approved treatment options** for BRAF V600 patients who do not have a BRAF V600E or V600K mutation

Despite limitations, current BRAF inhibitor market is **~\$2B**<sup>2</sup>

BRAF inhibitor market is estimated to grow to **~\$3B by 2028**<sup>2</sup>



## Potential Advantages of CFT1946, a Novel, Oral, BRAF V600 Mutant BiDAC degrader:

- ✓ Prevents BRAF V600 mutant **mono/heterodimer formation**<sup>1</sup>
- ✓ **Avoids paradoxical activation** seen with approved inhibitors<sup>1</sup>
- ✓ **Addresses MAPK pathway alterations** resulting from BRAF inhibitor resistance (e.g., BRAF splice variants, BRAF amplification)<sup>1</sup>
- ✓ **Specifically targets BRAF V600 mutations**, which includes BRAF V600 mutations beyond BRAF V600E
- ✓ Spares wild-type BRAF<sup>1</sup>, likely **avoiding AEs associated with inhibition of wild-type BRAF**
- ✓ Enables deep elimination of mutant BRAF signaling to **create potential durable responses** through degrader molecule recycling and catalytic effect

<sup>1</sup>Kreger B et al. Abstract 1658, AACR 2024; <sup>2</sup>Evaluate Pharma 2023 Adverse event (AE); Mitogen-activated protein kinase (MAPK)

# $Kp_{u,u}$ Results Demonstrate CFT1946's Ability to Cross the Blood Brain Barrier and Supports Activity in Preclinical Intracranial Metastatic Models

A375 BRAF V600E-Luc Intracranial Model



$Kp_{u,u}$  values for CFT1946 were experimentally measured using independent methods in two different species

The CFT1946 values of  $Kp_{u,u}$  range from 0.34 – 0.88

**These results demonstrate the ability of CFT1946 to cross the blood brain barrier and highlight the potential for drug delivery to CNS tumors**


Central nervous system (CNS)

# CFT1946 Phase 1/2 Dose Escalation Trial Continues to Progress Across BRAF V600 Mutant Driven Solid Tumors

## KEY INCLUSION CRITERIA<sup>1</sup>

- Evidence of BRAF V600 mutation obtained from tumor tissue or liquid biopsy
- BRAF V600 mutant measurable solid tumors with ≥1 prior line of SoC therapy for unresectable locally advanced or metastatic disease
- Melanoma patients must have received prior BRAF inhibitor therapy
- CRC, ATC, NSCLC or other non-CNS solid tumors: prior BRAF inhibitor therapy unless not available per SoC
- No patient with CNS involvement (primary tumor or metastatic disease), except if clinically stable

## MONOTHERAPY DOSE ESCALATION




## PRIMARY ENDPOINTS

- Safety and tolerability
- Determine RP2D/MTD

## SECONDARY ENDPOINTS

- Estimate anti-tumor activity
- Assess PK and PD

## PK, PD, ANTI-TUMOR ACTIVITY EVALUATION<sup>2</sup>



## Exploratory Expansion:

CFT1946 monotherapy in melanoma  
640 mg BID  
*Enrolling*

## Exploratory Expansion:

CFT1946 monotherapy in melanoma  
320 mg BID  
*Ongoing*

## Phase 1B:

CFT1946 in combination with cetuximab in CRC  
160 mg BID  
*Enrolling*

## Phase 1B:

CFT1946 in combination with trametinib for melanoma and NSCLC  
*Pending*

<sup>1</sup>NCT05668585. [www.clinicaltrials.gov](http://www.clinicaltrials.gov). Accessed 01/09/2024; <sup>2</sup>Evaluating additional patients for pharmacodynamic assessment pre- and post-drug exposure biopsies  
Colorectal cancer (CRC); Anaplastic thyroid cancer (ATC); Non-small cell lung cancer (NSCLC); Central nervous system (CNS); Standard of care (SoC); Dose Level (DL); Twice daily (BID); Recommended Phase 2 dose (RP2D); Maximum tolerated dose (MTD); Pharmacokinetic (PK); Pharmacodynamic (PD)

# CFT1946 Monotherapy Phase 1 Data Demonstrate Proof of Mechanism and Provide Early Evidence of Proof of Degradation Concept



## Proof of Mechanism

- ✓ **Well tolerated** and **highly selective degrader**, results in **no Grade  $\geq$  3 cutaneous adverse events**, which are commonly seen with wild-type BRAF inhibition
- ✓ **Increased drug exposure** observed with dose escalation
- ✓ **Degraded BRAF V600E** protein in all available post-treatment biopsies collected to date



## Proof of Degradation Concept

- ✓ Early evidence of monotherapy **anti-tumor activity** in patients who progressed after treatment with BRAF inhibitors
- ✓ Anti-tumor activity seen **across multiple BRAF V600 mutants**
- Degradation of mutant BRAF protein overcomes resistance mechanisms and results in potentially **deeper** and more **durable responses than BRAF inhibitors**



CFT1946 has the potential to **disrupt the treatment landscape** and become an **important option for patients with BRAF V600 mutant driven solid tumors**

# Well-Tolerated Monotherapy Safety Profile, Consistent With BRAF V600 Mutant Selectivity Design of CFT1946

- No DLTs
- Majority of TEAEs observed were mild to moderate
- No treatment-related SAEs
- No Grade  $\geq 3$  treatment-related cutaneous adverse events
- No new primary malignancies

## Summary of TEAEs $\geq 10\%$ of 36 patients treated with CFT1946

Preferred Term	Grade 1 n (%)	Grade 2 n (%)	Grade 3 n (%)	Grade 4 n (%)	Grade 5 n (%)	Total (n=36) n (%)
<b>Patients with any TEAEs<sup>^</sup></b>	3 (8)	14 (39)	11 (31)	2 (6)	1 (3) <sup>#</sup>	31 (86)
Anemia	1 (3)	4 (11)	2 (6)	0	0	7 (19)
Abdominal pain	4 (11)	1 (3)	2 (6)	0	0	7 (19)
Peripheral edema	5 (14)	1 (3)	0	0	0	6 (17)
Pyrexia	4 (11)	2 (6)	0	0	0	6 (17)
Fatigue	1 (3)	4 (11)	0	0	0	5 (14)
Lipase increased	3 (8)	2 (6)	0	0	0	5 (14)
Back pain	1 (3)	2 (6)	1 (3)	0	0	4 (11)
Hypophosphatemia	1 (3)	3 (8)	0	0	0	4 (11)
Constipation	1 (3)	2 (6)	0	0	0	4 (11) <sup>*</sup>

<sup>^</sup>A patient is only counted once with the highest severity and preferred term


<sup>#</sup>Patient had a fatal cerebrovascular accident not related to CFT1946

CTCAE v5.0 grading criteria; <sup>\*</sup>Grade missing for 1 patient with TEAE

Serious adverse events (SAEs); Dose limiting toxicities (DLTs); Treatment-related adverse events (TRAES); Treatment-emergent adverse events (TEAEs)

Source: ESMO Congress 2024; C4T data as of 7/19/2024








# Early Signs of Anti-tumor Activity: 59% (16/27) Patients Demonstrated Target Lesion Tumor Reductions With 11 Efficacy Evaluable Patients Continuing Treatment



\*Other tumor types include cholangiocarcinoma, non-small cell lung cancer, pancreatic carcinoma, and small intestine cancer; BRAF V600 mutation is V600E unless otherwise specified; #This patient did not receive prior BRAF inhibitor therapy, all other patients received prior BRAF inhibitor therapy. Dotted lines represent partial response (-30%, blue line) and progressive disease (20%, gray line) per RECIST v1.1.  
<sup>1</sup> Patient on 160 mg BID had 56.2% reduction on target lesion, progression on non-target lesion and a new lesion, hence assessed as PD for overall response;  
<sup>2</sup> Patient on 640 mg BID had PR confirmed after data cut off, and as of ESMO Congress (9/13/2024); <sup>3</sup> Patient on 160 mg BID had PD following first PR (-43.9%), hence assessed as SD for overall response; <sup>4</sup> Patient on 20 mg BID had unconfirmed PR, hence assessed as SD for overall response; <sup>5</sup> Patient on 160 mg BID had -29% reduction on target lesion, hence assessed as SD



# CFT1946 Has the Potential to Address Multiple Tumor Types With BRAF V600X Mutations Where BRAF Inhibitors Are Insufficient

	 BRAF V600X Mutation Rate	 2023 U.S. Incidence of BRAF V600X Patients <sup>4</sup>	 Approved BRAF Inhibitors	 BRAF Inhibitor Regimen mPFS <sup>5</sup>
 Melanoma	~35% <sup>1</sup>	~35,000	<ul style="list-style-type: none"> <li>• Dabrafenib</li> <li>• Encorafenib</li> <li>• Vemurafenib</li> </ul> <i>All used in combination with MEK inhibitors</i>	<b>11.4 months</b> (dabrafenib + trametinib in 1L+)
 Colorectal Cancer	5-10% <sup>2</sup>	~11,000	<ul style="list-style-type: none"> <li>• Encorafenib</li> </ul> <i>Used in combination with cetuximab (anti-EGFR)</i>	<b>4.2 months</b> (encorafenib + cetuximab in 2L+)
 Non-Small Cell Lung Cancer	1-2% <sup>3</sup>	~3,000	<ul style="list-style-type: none"> <li>• Dabrafenib</li> <li>• Encorafenib</li> </ul> <i>Both used in combination with MEK inhibitors</i>	<b>15.2 months</b> (dabrafenib + trametinib in 2L+)

Sources: 1. Owsley 2021 Exp Biol Med. 2. Paik 2011 J Clin Oncol. 3. Bylsma 2020 Cancer Med. 4. NCI SEER, consulting work done by Health Advances. 5. FDA Labels


# CFT8919

*Targeting EGFR L858R*

Non-Small Cell Lung Cancer (NSCLC)

# Potential for CFT8919 to Improve Outcomes for NSCLC Patients With EGFR L858R Mutations

## Strong Rationale for an EGFR L858R Degradable



### CFT8919 Key Properties

- Orally bioavailable
- Potent and selective against L858R, regardless of secondary mutations
- Allosteric binding



### Market Size

- ~\$6B approved EGFR inhibitor market<sup>1</sup>




### Progress to Date

- Achieved FDA clearance of U.S. IND
- Beta received CTA clearance from China's NMPA

Non-small cell lung cancer (NSCLC); Tyrosine Kinase Inhibitor (TKI); Osimertinib (Osi); Investigational New Drug (IND); Clinical Trial Application (CTA)  
Sources: Soria, J.C. et al. NEJM 378, 113–125 (2018); Sher, T. et al, Mayo Clin. Proc. 83, 355-367 (2008); 1. 2023 market size from EvaluatePharma.

# CFT8919 is a Potent, Oral, Allosteric, Mutant-selective Degradator of EGFR L858R




- CFT8919 exploits **allosteric binding site**, close to L858R activating mutation
- Allosteric binding site avoids known resistance-causing mutations in **orthosteric binding site**
- Allosteric binders do not require covalent binding through C797S and do not compete with orthosteric binding


**Allosteric binding avoids resistance mutations, wild-type activity, and is combinable with orthosteric inhibitors**

# CFT8919 is Selective for EGFR L858R and Active in a Setting of Osimertinib Resistance in Preclinical Models

## Specific for EGFR Exon 21 Mutants



## Active in setting of EGFR C797S



Source: C4T data on file; Keystone Symposium 2021  
Investigational New Drug Application (IND)

# C4T is On Track to Achieve All 2024 Goals, Progressing Multiple Clinical and Preclinical Programs

## Cemsidomide IKZF1/3

- **ASH 2024 (Dec.):** Present updated data from Phase 1 dose escalation +dex trial in R/R MM
- **ASH 2024 (Dec.):** Present data from Phase 1 dose escalation monotherapy trial in R/R NHL
- **By YE 2024:** Complete Phase 1 dose exploration in R/R MM and R/R NHL

## CFT1946 BRAF V600 Mutant

- ✓ **2Q 2024:** Present preclinical data demonstrating differentiated activity in BRAF V600 mutant driven melanoma, CRC, NSCLC, and brain metastasis models at AACR
- ✓ **ESMO Congress 2024:** Present monotherapy data from Phase 1 dose escalation trial in melanoma, CRC, NSCLC and other BRAF V600 mutant driven cancers

## CFT8919 EGFR L858R

- ✓ **2024:** Support trial start-up activities related to Betta's Phase 1 dose escalation trial in China

## Discovery

- ✓ **1Q 2024:** Collaboration with Merck KGaA, Darmstadt, Germany to discover two targeted protein degraders against critical oncogenic proteins
- ✓ **2024:** Deliver development candidate to collaboration partner

**Runway into 2027, Beyond Value Inflection Milestones**

Relapsed or refractory multiple myeloma (R/R MM); Relapsed or refractory non-Hodgkin lymphoma (R/R NHL); Colorectal cancer (CRC); Non-small cell lung cancer (NSCLC)